+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030- Product Image
Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030- Product Image
Sale

Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887490
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gynecological cancer drugs market is undergoing significant transformation, driven by a blend of scientific innovation, evolving treatment paradigms, and increasing complexity in both regulatory and commercial environments. Stakeholders face new challenges and opportunities as the landscape rapidly shifts toward patient-centric, data-driven solutions.

Market Snapshot: Gynecological Cancer Drugs Market Overview

The gynecological cancer drugs market grew from USD 10.35 billion in 2024 to USD 11.63 billion in 2025 and is projected to reach USD 20.68 billion by 2030 at a CAGR of 12.22%. This steady growth underscores the critical need for advanced therapeutics, improved patient outcomes, and adaptive commercial strategies across the global oncology sector.

Scope & Segmentation

This report delivers an in-depth analysis of the gynecological cancer drugs market, with detailed coverage of core therapeutic modalities, drug classes, distribution channels, and geographic markets. Segmentation emphasizes both commercial and clinical relevance, giving a comprehensive view across supply chains, end users, and innovation drivers.

  • End Users: Oncology clinics, outpatient clinics, private hospitals, public hospitals, specialty centers
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • Administration Routes: Intraperitoneal, intravenous (including bolus and infusion), oral (capsule, tablet)
  • Drug Classes: Chemotherapy agents (alkylating agents, platinum compounds, taxanes), hormonal therapy (anti-estrogens, aromatase inhibitors), immunotherapy (checkpoint inhibitors, vaccines), targeted therapy (angiogenesis inhibitors, PARP inhibitors, tyrosine kinase inhibitors)
  • Cancer Types: Cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (including China, India, Japan, Australia, and additional markets)
  • Leading Market Participants: F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Merck & Co., Inc., GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc., Novartis AG, Johnson & Johnson, Eisai Co., Ltd, Amgen Inc.

Key Takeaways for Decision-Makers

  • Recent advancements in targeted, biomarker-driven therapies and precision oncology are changing the standard of care, particularly in ovarian and endometrial malignancies.
  • Combination regimens integrating immunotherapy with anti-angiogenic agents or PARP inhibitors are enabling longer-lasting, better-tolerated responses.
  • Regulatory agencies are adapting, with expedited approvals and adaptive trials accelerating patient access to innovative treatments.
  • Digital health solutions and remote monitoring technologies are evolving, offering improved patient adherence and earlier identification of adverse events—enhancing overall therapy outcomes.
  • Strategic partnerships and acquisitions among leading pharmaceutical and biotech firms are fueling a robust and competitive ecosystem for drug development and commercialization.
  • Geographic differences in reimbursement, infrastructure maturity, and patient access demand region-specific approaches for optimal market penetration and growth.

Tariff Impact on the Gynecological Cancer Drugs Market

The introduction of new tariffs on imported active pharmaceutical ingredients and finished drug products in 2025 creates an additional layer of complexity. Manufacturers are recalibrating sourcing and pricing strategies to minimize disruptions, while downstream stakeholders such as pharmacies and distributors face challenges in inventory management and reimbursement. Leading companies are investing in regional production hubs and diversifying supplier networks to mitigate these risks, emphasizing the necessity for integrated supply chain management and agile procurement processes.

Methodology & Data Sources

The analysis is based on primary interviews with oncologists, payers, distributors, and patient advocacy groups, complemented by reviews of regulatory filings, clinical trial registries, and peer-reviewed literature. Proprietary databases and selective expert panels provided further validation, ensuring that findings accurately reflect the sector’s evolving landscape.

Why This Report Matters

  • Gain actionable insights for portfolio development, commercialization, and partnership decisions within the gynecological cancer drugs market.
  • Identify region- and segment-specific growth opportunities by benchmarking against peer strategies, regulatory shifts, and emerging technology adoption.
  • Support evidence-based decision-making through rigorous, cross-validated data on clinical progress, competitive positioning, and supply chain impacts.

Conclusion

The gynecological cancer drugs market is poised for sustained evolution as data-driven therapies, digital health integration, and adaptive strategies reshape the field. Organizations that anticipate regulatory, commercial, and regional trends will be best positioned to drive improved outcomes for both patients and stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gynecological Cancer Drugs Market, by End User
8.1. Introduction
8.2. Clinics
8.2.1. Oncology Clinics
8.2.2. Outpatient Clinics
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
8.4. Specialty Centers
9. Gynecological Cancer Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Gynecological Cancer Drugs Market, by Administration Route
10.1. Introduction
10.2. Intraperitoneal
10.3. Intravenous
10.3.1. Bolus
10.3.2. Infusion
10.4. Oral
10.4.1. Capsule
10.4.2. Tablet
11. Gynecological Cancer Drugs Market, by Drug Class
11.1. Introduction
11.2. Chemotherapy Agents
11.2.1. Alkylating Agents
11.2.2. Platinum Compounds
11.2.3. Taxanes
11.3. Hormonal Therapy
11.3.1. Anti-Estrogens
11.3.2. Aromatase Inhibitors
11.4. Immunotherapy
11.4.1. Checkpoint Inhibitors
11.4.2. Vaccines
11.5. Targeted Therapy
11.5.1. Angiogenesis Inhibitors
11.5.2. PARP Inhibitors
11.5.3. Tyrosine Kinase Inhibitors
12. Gynecological Cancer Drugs Market, by Cancer Type
12.1. Introduction
12.2. Cervical Cancer
12.3. Endometrial Cancer
12.4. Ovarian Cancer
12.5. Vulvar Cancer
13. Americas Gynecological Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gynecological Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gynecological Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. AstraZeneca PLC
16.3.3. Merck & Co., Inc.
16.3.4. GlaxoSmithKline plc
16.3.5. Clovis Oncology, Inc.
16.3.6. Pfizer Inc.
16.3.7. Novartis AG
16.3.8. Johnson & Johnson
16.3.9. Eisai Co., Ltd
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. GYNECOLOGICAL CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 87. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 88. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 92. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 100. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 161. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 166. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 167. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 168. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 171. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 174. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 184. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 200. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 205. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 206. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 209. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 210. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 212. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 219. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 223. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 270. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 271. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 300. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 301. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 302. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 303. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 304. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 309. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 310. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 311. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 313. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 314. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 315. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 316. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gynecological Cancer Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co., Ltd
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.68 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gynecological Cancer Drugs - Global Strategic Business Report - Product Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Gynecological Cancer Drugs Market Report 2025 - Product Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Women's Health Therapeutics Market by Therapeutic Area, Product Type, Distribution Channel, End-User - Global Forecast to 2030 - Product Image

Women's Health Therapeutics Market by Therapeutic Area, Product Type, Distribution Channel, End-User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From

About the Market

The Gynecological Cancer Drugs market is a specialized segment within the broader domain of Oncology Drugs, focusing on medications used in the prevention and treatment of cancers affecting the female reproductive organs. This category encompasses drugs for ovarian, cervical, uterine/endometrial, and other less common gynecologic cancers. Advances in the understanding of the pathophysiology of gynecologic cancers have led to the development of targeted therapies, immunotherapy, hormone therapies, and chemotherapy agents. The growth in this market is driven by a rising prevalence of gynecological cancers, increased awareness of women's health, and ongoing research and development leading to more precise and personalized treatment options. In the landscape of the Oncology Drugs sector, gynecological cancer treatments are vital because they address a distinct and critical patient population. Various market participants often collaborate with research institutions and engage in clinical trials to enhance existing treatments and innovate new therapeutic solutions, facilitating progress in women's oncological care. Prominent companies operating in the Gynecological Cancer Drugs market include Roche Holding AG, AstraZeneca, Novartis AG, Pfizer Inc., and Bristol-Myers Squibb Company. These firms are pivotal in the research and production of drugs that cater to gynecological oncology, continually advancing the standards of care through therapeutic breakthroughs and extensive research initiatives. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.